Clinical_predictors_for_buserelin_acetate_treatment_of_uterine_fibroids:_a_prospective_study_of_40_women._Buserelin_acetate,_a_luteinizing_hormone-releasing_hormone_agonist,_is_known_to_be_effective_in_the_shrinkage_of_uterine_fibroids._A_prospective_trial_was_undertaken_(1)_to_compare_the_efficacy_of_intranasal_(IN)_and_subcutaneous_(SC)_administration_of_buserelin_acetate_and_(2)_to_assess_if_tumor_regression_correlated_with_fibroid_size_and/or_patient_age._Forty_patients_were_randomly_allocated_to_receive_6_months_of_either_IN_buserelin_acetate_(n_=_21)_or_SC_buserelin_acetate_(n_=_19)._Four_patients_did_not_complete_the_study_and_were_excluded_from_statistical_analysis._Fibroid_regression_occurred_in_all_36_patients._Overall_regression_to_66%_or_less_of_the_initial_fibroid_volume_occurred_in_70%_of_subjects._There_was_no_significant_difference_in_fibroid_shrinkage_between_the_two_administration_routes._A_significant_positive_correlation_was_found_between_initial_fibroid_size_and_subsequent_fibroid_regression,_with_larger_tumors_being_more_likely_to_shrink_than_smaller_fibroids._No_correlation_was_found_between_the_patient's_age_and_the_extent_of_fibroid_regression.